News | December 21, 2025
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Subscribe To Our Newsletter & Stay Updated
